1st Apr 2005 07:00
Provalis PLC01 April 2005 For Immediate Release 1st April 2005 Provalis plc Retirement of Dr David Bloxham as a Non-Executive Director Provalis plc (LSE: PRO; NASDAQ: PVLS), the International Medical Diagnostics andPharmaceuticals Group, announces that Dr David Bloxham has retired as anon-executive Director with effect from 31st March 2005. On 18th February 2005 Provalis announced the appointment of Dr Alan Aikman as anon-executive Director, and at the same time announced that Dr Bloxham wouldretire from the Board on 31st May 2005. However, as Dr Aikman has alreadyfamiliarised himself with the Company's businesses and been appointed asChairman of the Remuneration Committee in succession to David Bloxham, DrBloxham has decided to retire slightly earlier than first announced. Frank Harding, Chairman of Provalis, said, "I would like to take this furtheropportunity to thank David for his significant contribution to the Group'sstrategic development and to wish him well for the future." END Provalis' Website; http://www.provalis.com "Safe Harbor" Statement under the US Private Securities Litigation Reform Act of1995: Statements in this announcement that relate to future plans, expectations,events, performances and the like are forward-looking statements as defined inthe US Private Securities Litigation Reform Act of 1995. Actual results ofevents could differ materially from those described in the forward-lookingstatements due to a variety of factors. Such factors include, among others: theviability of the Group's products, which are at various stages of development;the generation of sufficient operating cash flow by the Group's pharmaceuticaland medical diagnostic businesses to finance the ongoing development of thesebusinesses as well as the Group's research and development activities; thesuccess of the Group's research and development strategy and activities;uncertainties related to future clinical trial results and the associatedregulatory process; the execution and success of collaborative agreements withthird parties; availability and level of reimbursement for the Group's productsfrom government health administration authorities or other third-party payors;the rate of net cash utilisation within the Group and, hence, the Group'spossible need for additional capital in the short, medium and/or long term; theGroup's intellectual property position and the success of patent applicationsfor its products and technologies; the Group's dependence on key personnel;general business and economic conditions; the impact of future laws, regulationsand policies; stock market trends in the Group's sector; and other factorsbeyond the Group's control that may cause the Group's available capitalresources to be used more quickly than expected. These and other factors thatcould affect the Company's future results are more fully described in itsfilings with the US Securities and Exchange Commission, in particular the latest20-F filing, copies of which are available from the Company Secretary at theCompany's registered address. For further information:- Dr Phil Gould, Chief Executive Officer, Provalis plc Tel: 01244 833463Mr Peter Bream, Finance Director, Provalis plc Tel: 01244 833552Mr Lee Greenbury, Company Secretary, Provalis plc Tel: 01244 833402Lisa Baderoon, Buchanan Communications Tel: 020 7466 5000 Notes to Editors Provalis plc (LSE: PRO; NASDAQ: PVLS) is an international healthcare group withtwo operating businesses:- • Medical Diagnostics - develops medical diagnostic products forchronic disease management for sale to world markets. The business' principalproducts are in2it(TM) A1c and Glycosal(R), both diabetes diagnostic tests, andOsteosal(R), a diagnostic test for osteoporosis. • Pharmaceuticals - sells and markets its own, and third party,branded, prescription medicines in the UK and Ireland to GPs and hospitalsthrough its regionally managed sales force. The business' principal product isDiclomax(R), a medicine for use in the treatment of musculo-skeletal disorders,and it also sells products in the areas of osteoporosis, migraine anddermatology. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Proservice Bldg